{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:21:45Z","timestamp":1740126105837,"version":"3.37.3"},"reference-count":53,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,5,30]],"date-time":"2018-05-30T00:00:00Z","timestamp":1527638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Broegelmann Foundation"},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Western Norway Regional Health Authorities"},{"name":"Faculty of Medicine"},{"DOI":"10.13039\/501100005036","name":"Universitetet i Bergen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005036","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"DOI":"10.1111\/bjd.16269","type":"journal-article","created":{"date-parts":[[2017,12,24]],"date-time":"2017-12-24T10:58:24Z","timestamp":1514113104000},"source":"Crossref","is-referenced-by-count":4,"title":["Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab"],"prefix":"10.1093","author":[{"given":"A.K.","family":"Aarebrot","sequence":"first","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4250-1789","authenticated-orcid":false,"given":"S.M.","family":"Solberg","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"},{"name":"Department of Dermatology; Haukeland University Hospital; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Davies","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.I.","family":"Bader","sequence":"additional","affiliation":[{"name":"Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBiRD); Department of Rheumatology; Haukeland University Hospital; Bergen Norway"},{"name":"Department of Clinical Science; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.D.","family":"Holmes","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gavasso","sequence":"additional","affiliation":[{"name":"Neuroimmunology Laboratory; Department of Neurology; Haukeland University Hospital; Bergen Norway"},{"name":"Department of Clinical Medicine; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.T.","family":"Bryceson","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"},{"name":"Centre for Hematology and Regenerative Medicine; Department of Medicine; Karolinska Institutet; Karolinska University Hospital Huddinge; Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Jonsson","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"},{"name":"Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBiRD); Department of Rheumatology; Haukeland University Hospital; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.F.","family":"Sandvik","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Haukeland University Hospital; Bergen Norway"},{"name":"Department of Clinical Medicine; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2199-2315","authenticated-orcid":false,"given":"S.","family":"Appel","sequence":"additional","affiliation":[{"name":"Broegelmann Research Laboratory; Department of Clinical Science; University of Bergen; Bergen Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,30]]},"reference":[{"key":"10.1111\/bjd.16269-BIB0001|bjd16269-cit-0001","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"10.1111\/bjd.16269-BIB0002|bjd16269-cit-0002","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16269-BIB0003|bjd16269-cit-0003","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00741841","article-title":"The nature and frequency of the histological changes found in psoriasis vulgaris","volume":"257","author":"Beek","year":"1977","journal-title":"Arch Dermatol Res"},{"key":"10.1111\/bjd.16269-BIB0004|bjd16269-cit-0004","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol Clin"},{"key":"10.1111\/bjd.16269-BIB0005|bjd16269-cit-0005","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.1111\/jdv.14367","article-title":"Prediction of 30-year cardiovascular disease risk in psoriatic population","volume":"31","author":"Buligan","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16269-BIB0006|bjd16269-cit-0006","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-017-0293-x","article-title":"Association between inflammatory skin disease and cardiovascular and cerebrovascular co-morbidities in us adults: analysis of nationwide inpatient sample data","volume":"18","author":"Kwa","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/bjd.16269-BIB0007|bjd16269-cit-0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/CIRCULATIONAHA.116.026859","article-title":"Coronary plaque characterization in psoriasis reveals high-risk features that improve after treatment in a prospective observational study","volume":"136","author":"Lerman","year":"2017","journal-title":"Circulation"},{"key":"10.1111\/bjd.16269-BIB0008|bjd16269-cit-0008","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1056\/NEJM200107263450403","article-title":"Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes","volume":"345","author":"Ellis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16269-BIB0009|bjd16269-cit-0009","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/ced.12845","article-title":"Circulating T-helper 17 cells and associated cytokines in psoriasis","volume":"41","author":"Chhabra","year":"2016","journal-title":"Clin Exp Dermatol"},{"key":"10.1111\/bjd.16269-BIB0010|bjd16269-cit-0010","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.intimp.2015.11.005","article-title":"Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-alpha treatment in psoriasis","volume":"29","author":"Luan","year":"2015","journal-title":"Int Immunopharmacol"},{"key":"10.1111\/bjd.16269-BIB0011|bjd16269-cit-0011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000330330","article-title":"Th1, Th2, Th17 and regulatory T cell pattern in psoriatic patients: modulation of cytokines and gene targets induced by etanercept treatment and correlation with clinical response","volume":"223","author":"Quaglino","year":"2011","journal-title":"Dermatology"},{"key":"10.1111\/bjd.16269-BIB0012|bjd16269-cit-0012","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bjd.12355","article-title":"Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis","volume":"169","author":"Dowlatshahi","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16269-BIB0013|bjd16269-cit-0013","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0014|bjd16269-cit-0014","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.0906-6705.2004.00205.x","article-title":"Biology of tumor necrosis factor-alpha- implications for psoriasis","volume":"13","author":"Schottelius","year":"2004","journal-title":"Exp Dermatol"},{"key":"10.1111\/bjd.16269-BIB0015|bjd16269-cit-0015","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.4049\/jimmunol.160.6.2742","article-title":"Induction of Jak\/STAT signaling by activation of the type 1 TNF receptor","volume":"160","author":"Guo","year":"1998","journal-title":"J Immunol"},{"key":"10.1111\/bjd.16269-BIB0016|bjd16269-cit-0016","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1600-065X.2012.01104.x","article-title":"IkappaB kinase regulation of the TPL-2\/ERK MAPK pathway","volume":"246","author":"Gantke","year":"2012","journal-title":"Immunol Rev"},{"key":"10.1111\/bjd.16269-BIB0017|bjd16269-cit-0017","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/jid.2015.103","article-title":"Association with genetic variants in the IL-23 and NF-kappaB pathways discriminates between mild and severe psoriasis skin disease","volume":"135","author":"Nikamo","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0018|bjd16269-cit-0018","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","article-title":"The immunogenetics of psoriasis: a comprehensive review","volume":"64","author":"Harden","year":"2015","journal-title":"J Autoimmun"},{"key":"10.1111\/bjd.16269-BIB0019|bjd16269-cit-0019","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/nrc2734","article-title":"STATs in cancer inflammation and immunity: a leading role for STAT3","volume":"9","author":"Yu","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1111\/bjd.16269-BIB0020|bjd16269-cit-0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/exd.12128","article-title":"Studies of Jak\/STAT3 expression and signalling in psoriasis identifies a STAT3-Ser727 phosphorylation as a modulator of transcriptional activity","volume":"22","author":"Andr\u00e9s","year":"2013","journal-title":"Exp Dermatol"},{"key":"10.1111\/bjd.16269-BIB0021|bjd16269-cit-0021","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.181.7.4733","article-title":"Induction of IL-17\u00a0+\u00a0 T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis","volume":"181","author":"Kryczek","year":"2008","journal-title":"J Immunol"},{"key":"10.1111\/bjd.16269-BIB0022|bjd16269-cit-0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jdermsci.2015.11.007","article-title":"Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3","volume":"81","author":"Yang","year":"2016","journal-title":"J Dermatol Sci"},{"key":"10.1111\/bjd.16269-BIB0023|bjd16269-cit-0023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/jid.2010.255","article-title":"Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor","volume":"131","author":"Miyoshi","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0024|bjd16269-cit-0024","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","article-title":"Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity","volume":"26","author":"Schafer","year":"2014","journal-title":"Cell Signal"},{"key":"10.1111\/bjd.16269-BIB0025|bjd16269-cit-0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem"},{"key":"10.1111\/bjd.16269-BIB0026|bjd16269-cit-0026","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","article-title":"p38(MAPK): stress responses from molecular mechanisms to therapeutics","volume":"15","author":"Coulthard","year":"2009","journal-title":"Trends Mol Med"},{"key":"10.1111\/bjd.16269-BIB0027|bjd16269-cit-0027","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.tem.2006.07.008","article-title":"Seven-transmembrane receptor signalling and ERK compartmentalization","volume":"17","author":"Caunt","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"10.1111\/bjd.16269-BIB0028|bjd16269-cit-0028","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.clim.2003.11.009","article-title":"Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications","volume":"110","author":"Krutzik","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1111\/bjd.16269-BIB0029|bjd16269-cit-0029","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s40268-016-0152-x","article-title":"Efficacy of immunobiologic and small molecule inhibitor drugs for psoriasis: a systematic review and meta-analysis of randomized clinical trials","volume":"17","author":"Carvalho","year":"2017","journal-title":"Drugs R D"},{"key":"10.1111\/bjd.16269-BIB0030|bjd16269-cit-0030","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.yexcr.2011.01.024","article-title":"Anti-cytokine therapies for psoriasis","volume":"317","author":"Nograles","year":"2011","journal-title":"Exp Cell Res"},{"key":"10.1111\/bjd.16269-BIB0031|bjd16269-cit-0031","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1111\/bjd.16269-BIB0032|bjd16269-cit-0032","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.16269-BIB0033|bjd16269-cit-0033","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"Suppl. 1","key":"10.1111\/bjd.16269-BIB0034|bjd16269-cit-0034","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1586\/1744666X.2015.1090310","article-title":"Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe","volume":"11","author":"Muller-Ladner","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1111\/bjd.16269-BIB0035|bjd16269-cit-0035","doi-asserted-by":"crossref","first-page":"756","DOI":"10.2174\/1389203717666160226144618","article-title":"A comprehensive overview on biosimilars","volume":"17","author":"Kadam","year":"2016","journal-title":"Curr Protein Pept Sci"},{"key":"10.1111\/bjd.16269-BIB0036|bjd16269-cit-0036","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.clinthera.2017.03.014","article-title":"Comparing originator biologics and biosimilars: a review of the relevant issues","volume":"39","author":"Blandizzi","year":"2017","journal-title":"Clin Ther"},{"key":"10.1111\/bjd.16269-BIB0037|bjd16269-cit-0037","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jim.2016.06.007","article-title":"An optimized multiplex flow cytometry protocol for the analysis of intracellular signaling in peripheral blood mononuclear cells","volume":"436","author":"Davies","year":"2016","journal-title":"J Immunol Methods"},{"key":"10.1111\/bjd.16269-BIB0038|bjd16269-cit-0038","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/sji.12572","article-title":"Assays for infliximab drug levels and antibodies: a matter of scales and categories","volume":"86","author":"Bader","year":"2017","journal-title":"Scand J Immunol"},{"key":"10.1111\/bjd.16269-BIB0039|bjd16269-cit-0039","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.a.10072","article-title":"Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events","volume":"55","author":"Krutzik","year":"2003","journal-title":"Cytometry A"},{"key":"10.1111\/bjd.16269-BIB0040|bjd16269-cit-0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nmeth872","article-title":"Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling","volume":"3","author":"Krutzik","year":"2006","journal-title":"Nat Methods"},{"key":"10.1111\/bjd.16269-BIB0041|bjd16269-cit-0041","article-title":"Web-based analysis and publication of flow cytometry experiments","volume":"10","author":"Kotecha","year":"2010","journal-title":"Curr Protoc Cytom"},{"key":"10.1111\/bjd.16269-BIB0042|bjd16269-cit-0042","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16269-BIB0043|bjd16269-cit-0043","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-alpha antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0044|bjd16269-cit-0044","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamacardio.2017.1213","article-title":"Association between skin and aortic vascular inflammation in patients with psoriasis: a case-cohort study using positron emission tomography\/computed tomography","volume":"2","author":"Dey","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1111\/bjd.16269-BIB0045|bjd16269-cit-0045","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/jid.2014.295","article-title":"Immunogenicity of biotherapy used in psoriasis: the science behind the scenes","volume":"135","author":"Jullien","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0046|bjd16269-cit-0046","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/dth.12160","article-title":"Factors affecting response to biologic treatment in psoriasis","volume":"27","author":"Karczewski","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1111\/bjd.16269-BIB0047|bjd16269-cit-0047","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.sder.2010.03.001","article-title":"New insights in the immunologic basis of psoriasis","volume":"29","author":"Nograles","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"10.1111\/bjd.16269-BIB0048|bjd16269-cit-0048","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/08916934.2014.897333","article-title":"Chronic inflammatory diseases: do immunological patterns drive the choice of biotechnology drugs? A critical review","volume":"47","author":"Sozzani","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1111\/bjd.16269-BIB0049|bjd16269-cit-0049","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1038\/jid.2014.268","article-title":"IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood","volume":"134","author":"Wang","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0050|bjd16269-cit-0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jid.2016.09.015","article-title":"Shrinking the psoriasis assessment gap: early gene-expression profiling accurately predicts response to long-term treatment","volume":"137","author":"Correa da Rosa","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16269-BIB0051|bjd16269-cit-0051","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/j.jaci.2016.01.024","article-title":"Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren's signature correlating with disease activity and glandular inflammation","volume":"137","author":"Mingueneau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.16269-BIB0052|bjd16269-cit-0052","doi-asserted-by":"crossref","first-page":"ii104","DOI":"10.1136\/annrheumdis-2012-203037","article-title":"Biomarkers in psoriasis and psoriatic arthritis","volume":"72","author":"Villanova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/bjd.16269-BIB0053|bjd16269-cit-0053","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ddtec.2005.08.010","article-title":"Phospho-specific flow cytometry in drug discovery","volume":"2","author":"Clutter","year":"2005","journal-title":"Drug Discov Today Technol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16269","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16269\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T06:01:18Z","timestamp":1693375278000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/179\/2\/371\/6730908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,30]]},"references-count":53,"URL":"https:\/\/doi.org\/10.1111\/bjd.16269","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"type":"print","value":"0007-0963"}],"subject":[],"published":{"date-parts":[[2018,5,30]]}}}